The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2025
Synopsis
The global Chronic Obstructive Pulmonary Disorder (COPD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition characterized by persistent airflow limitation that makes it difficult to breathe. COPD encompasses a group of diseases, with the most common being emphysema and chronic bronchitis.
Emphysema involves the destruction of the air sacs in the lungs, while chronic bronchitis is marked by inflammation and narrowing of the airways. Symptoms include shortness of breath, chronic cough, excessive mucus production, wheezing, and tightness in the chest. COPD is often caused by long-term exposure to irritants, such as cigarette smoke, air pollution, and occupational dust or chemicals.
The condition is progressive and can significantly impact an individual's quality of life. In advanced stages, COPD can result in severe respiratory complications and exacerbations, potentially leading to hospitalizations.
Treatment for COPD typically involves a combination of medication, pulmonary rehabilitation, oxygen therapy, and in severe cases, surgical intervention such as lung volume reduction surgery or lung transplantation. Quitting smoking, avoiding lung irritants, and getting vaccinations to prevent respiratory infections are also essential components of COPD management.
COPD is a major public health concern globally, as it can cause significant morbidity and mortality. Early diagnosis, proper management, and lifestyle modifications are critical for maintaining the respiratory function and improving the well-being of individuals living with COPD.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disorder (COPD).
Report Scope
The Chronic Obstructive Pulmonary Disorder (COPD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Obstructive Pulmonary Disorder (COPD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disorder (COPD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Segment by Type
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Chronic Obstructive Pulmonary Disorder (COPD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition characterized by persistent airflow limitation that makes it difficult to breathe. COPD encompasses a group of diseases, with the most common being emphysema and chronic bronchitis.
Emphysema involves the destruction of the air sacs in the lungs, while chronic bronchitis is marked by inflammation and narrowing of the airways. Symptoms include shortness of breath, chronic cough, excessive mucus production, wheezing, and tightness in the chest. COPD is often caused by long-term exposure to irritants, such as cigarette smoke, air pollution, and occupational dust or chemicals.
The condition is progressive and can significantly impact an individual's quality of life. In advanced stages, COPD can result in severe respiratory complications and exacerbations, potentially leading to hospitalizations.
Treatment for COPD typically involves a combination of medication, pulmonary rehabilitation, oxygen therapy, and in severe cases, surgical intervention such as lung volume reduction surgery or lung transplantation. Quitting smoking, avoiding lung irritants, and getting vaccinations to prevent respiratory infections are also essential components of COPD management.
COPD is a major public health concern globally, as it can cause significant morbidity and mortality. Early diagnosis, proper management, and lifestyle modifications are critical for maintaining the respiratory function and improving the well-being of individuals living with COPD.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disorder (COPD).
Report Scope
The Chronic Obstructive Pulmonary Disorder (COPD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Obstructive Pulmonary Disorder (COPD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disorder (COPD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Segment by Type
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Short-Acting Bronchodilators
1.2.3 Corticosteroids
1.2.4 Methylxanthines
1.2.5 Long-Acting Bronchodilators
1.2.6 Phosphodiesterase-4 Inhibitors
1.2.7 Others
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2019-2030)
2.2 Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2019-2024)
2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2025-2030)
2.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics
2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends
2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2019-2024)
3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2023
3.5 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served
3.6 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2019-2024)
4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2025-2030)
5 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2019-2024)
5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2019-2030)
6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024)
6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2019-2030)
7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024)
7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2019-2030)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2019-2030)
9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024)
9.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2019-2030)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Detail
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Ario Pharma
11.8.1 Ario Pharma Company Detail
11.8.2 Ario Pharma Business Overview
11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.8.5 Ario Pharma Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.9.5 Roche Recent Development
11.10 Ache
11.10.1 Ache Company Detail
11.10.2 Ache Business Overview
11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.10.5 Ache Recent Development
11.11 Almirall
11.11.1 Almirall Company Detail
11.11.2 Almirall Business Overview
11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.11.5 Almirall Recent Development
11.12 Aquinox Pharmaceuticals
11.12.1 Aquinox Pharmaceuticals Company Detail
11.12.2 Aquinox Pharmaceuticals Business Overview
11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.12.5 Aquinox Pharmaceuticals Recent Development
11.13 Asmacure
11.13.1 Asmacure Company Detail
11.13.2 Asmacure Business Overview
11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.13.5 Asmacure Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Detail
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
11.14.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
